dm+d

Unassigned

New Medicines

ResVaxRespiratory syncytial virus - prevention

Information

ResVax
Vaccine
Not Known
Novavax

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

A recombinant virus-like particle (VLP) vaccine
RSV is one of the common viruses that cause coughs and colds in winter. In temperate climates such as the UK, RSV occurs regularly each year, peaking over the winter. For a small number of people at risk of more severe disease, RSV infection can cause pneumonia or even death. RSV is a common cause of bronchiolitis in infants. Between Q3 2019 and Q1 2020, 3,053 confirmed RSV cases (2,903 hospitalised to lower level of care & 150 in ICU/HDU) were reported from 16 hospitals. [17]
Respiratory syncytial virus - prevention
Intramuscular

Respiratory syncytial virus infection prophylaxis in pregnant woman population to prevent illness in infants during first months of life by transfer of maternal antibodies

Information

Vaccine
GlaxoSmithKline
GlaxoSmithKline

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Respiratory syncytial virus (RSV) recombinant subunit pre-fusion antigen (RSVPreF3)
RSV is one of the common viruses that cause coughs and colds in winter. In temperate climates such as the UK, RSV occurs regularly each year, peaking over winter. For most people, RSV infection causes a mild respiratory illness. For a small number of people who are at risk of more severe respiratory disease, RSV infection might cause pneumonia or even death. RSV is the most common cause of bronchiolitis in infants. There were 10,941 hospital admissions due to RSV infections in 2019-20 [2,3].
Respiratory syncytial virus infection prophylaxis in pregnant woman population to prevent illness in infants during first months of life by transfer of maternal antibodies
Intramuscular

Respiratory syncytial virus (RSV) infection - prevention in infants by immunisation to pregnant women

Information

Vaccine
Pfizer
Pfizer

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

The vaccine uses crystal structure of a key viral protein to elicit immune response against respiratory syncytial virus target [1]
RSV is one of the common viruses that cause coughs and colds in winter. In temperate climates such as the UK, RSV occurs regularly each year, peaking over winter. For most people, RSV infection causes a mild respiratory illness. For a small number of people who are at risk of more severe respiratory disease, RSV infection might cause pneumonia or even death. RSV is the most common cause of bronchiolitis in infants. There were 10,941 hospital admissions due to RSV infections in 2019-20.
Respiratory syncytial virus (RSV) infection - prevention in infants by immunisation to pregnant women
Intramuscular

Respiratory syncytial virus (RSV) infection - prevention in adults

Information

Vaccine
Pfizer
Pfizer

Development and Regulatory status

Phase II Clinical Trials
None
Phase III Clinical Trials

Category

The vaccine uses crystal structure of a key viral protein to elicit immune response against respiratory syncytial virus target [1]
RSV is one of the common viruses that cause coughs and colds in winter. In temperate climates such as the UK, RSV occurs regularly each year, peaking over winter. For most people, RSV infection causes a mild respiratory illness. For a small number of people who are at risk of more severe respiratory disease, RSV infection might cause pneumonia or even death. RSV is the most common cause of bronchiolitis in infants. There were 10,941 hospital admissions due to RSV infections in 2019-20.
Respiratory syncytial virus (RSV) infection - prevention in adults
Intramuscular

Respiratory syncytial virus infection - prevention in adults aged 60 and over

Information

Vaccine
Janssen
Janssen

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Respiratory syncytial virus (RSV) fusion (F) protein fusion (F) protein recombinant nanoparticle vaccine (adjuvanted)
RSV is one of the common viruses that cause coughs and colds in winter. In temperate climates such as the UK, RSV occurs regularly each year, peaking over the winter. For a small number of people at risk of more severe disease, RSV infection can cause pneumonia or even death. RSV is a common cause of bronchiolitis in infants. Between Q3 2019 and Q1 2020, 3,053 confirmed RSV cases (2,903 hospitalised to lower level of care & 150 in ICU/HDU) were reported from 16 hospitals [1].
Respiratory syncytial virus infection - prevention in adults aged 60 and over
Intramuscular